Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Denali Hunter Data
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Aug 31, 2022 10:12am
121 Views
Post# 34932148

RE:RE:RE:Denali Hunter Data

RE:RE:RE:Denali Hunter DataI wouldn't be too quick to discount Denali, prophetofphax. They're the company worth USD $3.4 billion today. Bioasis is worth CDN $12.3 million today.

So, who gets Bioasis's Hunter xB3-LSD drug? Does it already belong to Chiesi? I don't know but that wouldn't surprise me, given the secrecy and obliqueness of Bioasis's documentation and filings.

Would Protalix play a part in cheap production with ProCellEx? Where is Chiesi after more than two years?

As far as Bioasis having a "strategic portfolio of LSDs with Chiesi" I think that Bioasis sold the rights to those LSDs with only very low milestone payments possibly due and probably a very low royalty rate. That is NOT a strategic partnership. That's like buying a pickup truck and claiming you're in a strategic partnership with the automaker.

Bioasis's only claim to Fabry is with xB3-004 (IL1-Ra) and its treatment of neuropathic pain caused by Fabry, totally different than an enzyme replacement therapy for the disease.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities